Derma Sciences' Medihoney posted double-digit sales growth during the 1st quarter and the wound care product continues to gather fans around the world, says the company's CEO Ed Quilty. Quilty says the company added nearly 30 people to his sales and marketing staff in the first quarter of 2014 to introduce more clinicians to Medihoney. He also says the company's wound healing and scar reduction drug DSC 127 is in phase III testing and the company should have a data readout at the end of 2015. Finally, Quilty says the company is growing its presence in Europe and now has distributors in more than 20 countries.
Stocks in this video: